Agilent is pleased to announce that BIOVECTRA, a Canada-based specialized Contract Development and Manufacturing Organization (CDMO), is now part of our company. By joining together, Agilent and BIOVECTRA will offer our pharmaceutical customers an even broader range of active pharmaceutical ingredient (API) manufacturing capabilities for targeted therapeutics. The following frequently-asked-questions provide current and future customers of Agilent and BIOVECTRA general information, new capabilities we can now offer, and how to learn more.

FAQs

Q: I’m a current customer of BIOVECTRA. Who is my contact going forward?

Please continue working with your existing BIOVECTRA representative or team as usual. If you don’t have a regular contact, you can always reach the BIOVECTRA team.

Q: I’m a current customer of Agilent’s oligonucleotide CDMO. How does this acquisition affect me?

This acquisition will enable Agilent to provide our customers even more specialized manufacturing capabilities for targeted therapeutics, from sterile fill-finish to a single source for gene-editing technology.

To learn more about our expanded capabilities and how they may benefit your programs in the future, contact our team.

Q: What new CDMO offerings does BIOVECTRA bring to Agilent?

BIOVECTRA brings valuable services and capabilities to Agilent, including:

• sterile fill-finish
• pDNA and mRNA capabilities
• LNP formulation; and
• expertise in ADCs, HPAPIs, and peptide purification

Learn more about these offerings at Biovectra.com and contact the BIOVECTRA team with any questions about them.

Like Agilent, BIOVECTRA can also manufacture large quantities of material to support clinical-to-commercial needs.

Q: Agilent is a leader in therapeutic oligonucleotides. What synergies does BIOVECTRA bring to this expertise?

By combining BIOVECTRA’s complementary capabilities in biologics with our expertise in gRNA, Agilent will be able to provide customers with a single source for gene-editing technology. To learn more, email us.